The India’s Contract Development and Manufacturing Organization (CDMO) market is experiencing robust growth, emerging as a global hub for pharmaceutical outsourcing. As of 2024, the market is valued at US$ 22.1 billion, and is projected to reach US$ 54.7 billion by 2031, registering a CAGR of 13.8% during the forecast period. This exponential rise is largely attributed to India’s well-established pharmaceutical infrastructure, cost-efficiency, skilled workforce, and compliance with international regulatory standards.
Key growth drivers include the global patent cliff leading to rising demand for generics and biosimilars, increasing outsourcing by global pharmaceutical companies, and favorable government initiatives such as ‘Make in India’ and the PLI Scheme. Among the segments, contract manufacturing services lead the market, primarily due to India’s ability to produce large volumes at competitive prices. Geographically, South India, especially regions like Hyderabad and Bangalore, dominates the market, thanks to their concentration of biotech parks, R&D hubs, and manufacturing facilities.
Key Highlights from the Report:
• India CDMO Market to grow at a CAGR of 13.8% from 2024 to 2031.
• Contract Manufacturing Services segment is projected to grow at 14.6% CAGR.
• Small molecules segment to lead, with a CAGR of 14.1% through 2031.
• India benefits from cost-effective manufacturing and skilled labor availability.
• Surge in generics and biosimilars demand is fueling CDMO market growth.
• Favorable government initiatives like PLI and Make in India support market expansion.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34955
Market Segmentation Analysis
The India CDMO market is segmented across several verticals to reflect the diverse services and product offerings available.
By Product Type:
The market is broadly categorized into small molecules, large molecules (biologics), vaccines, and advanced therapeutics. Small molecules dominate the segment, owing to India’s legacy in manufacturing generics and APIs. The cost-effectiveness and mature infrastructure for small molecule manufacturing keep this segment in the lead. On the other hand, biologics and vaccines are witnessing faster growth rates, albeit from a smaller base, driven by global demand and increasing investment in biotech infrastructure.
By Service Type:
India’s CDMO market is divided into contract manufacturing services and contract development services. The former remains the dominant segment, accounting for the largest share, primarily because India offers economies of scale in bulk production of APIs and Finished Dosage Forms (FDFs). However, contract development services—which include R&D, formulation development, and clinical trials—are gaining traction as companies shift toward end-to-end CDMO partnerships.
By End-User:
Key end-users include pharmaceutical companies, biotech firms, and research institutions. Pharmaceutical companies form the bulk of the clientele, outsourcing both development and manufacturing processes to Indian CDMOs. Biotech firms, particularly those from North America and Europe, increasingly rely on Indian partners for cost-effective biologic manufacturing.
Regional Insights
Regionally, South India remains the powerhouse of the Indian CDMO landscape. Cities like Hyderabad, often referred to as the “Genome Valley of India,” and Bangalore, known for its biotech innovation, are at the forefront. These regions host clusters of pharmaceutical manufacturing plants, R&D centers, and SEZs that are tailor-made to support CDMO operations.
Western India, especially Mumbai and Pune, also plays a significant role, primarily due to its proximity to ports, better logistics, and presence of leading pharmaceutical companies. Northern India is growing steadily with support from state governments and emerging biotech parks, while Eastern India still represents an underutilized opportunity in the CDMO landscape.
Market Drivers
Cost Efficiency and Skilled Workforce
India’s CDMO industry thrives on its unique value proposition—high-quality pharmaceutical manufacturing at a fraction of the global cost. With significantly lower labor and infrastructure costs, India offers a sustainable competitive advantage. Coupled with a vast pool of scientifically trained professionals, CDMOs in India can deliver high-volume, high-quality manufacturing aligned with international regulatory requirements.
Rise in Generics and Biosimilars
The expiration of key drug patents globally has led to an unprecedented demand for generics and biosimilars. India, already the largest global supplier of generic drugs, is well-equipped to meet this need. Its CDMOs have proven capabilities in handling large-scale manufacturing, regulatory filing, and compliance—making them the go-to partners for pharmaceutical giants.
Market Restraints
Infrastructure and Technological Constraints
Despite the sector’s strengths, infrastructure limitations—particularly in the biologics and advanced therapeutics space—pose a significant challenge. While India has mastered small molecule manufacturing, it still lags in high-tech capabilities required for cell and gene therapies, monoclonal antibodies, and mRNA-based vaccines. Moreover, inadequate investment in cutting-edge R&D and limited access to advanced bioprocessing equipment restrict India’s growth in complex biologic segments.
Market Opportunities
Increasing Outsourcing Trends
Global pharmaceutical companies are shifting towards asset-light models, outsourcing not just manufacturing but also research, formulation, and clinical development. This trend opens up massive opportunities for Indian CDMOs that can offer end-to-end integrated services. With improved regulatory adherence and expanding biotech capabilities, Indian firms are increasingly being viewed as strategic, long-term partners rather than mere service providers.
Reasons to Buy the Report:
• Gain insights into a rapidly growing market projected to reach US$ 54.7 Bn by 2031.
• Understand key trends and dynamics shaping the India CDMO landscape.
• Benchmark leading players and learn from recent strategic developments.
• Identify new investment opportunities in biologics, biosimilars, and vaccines.
• Leverage detailed segmentation to tailor market entry or expansion strategies.
Frequently Asked Questions (FAQs)
How Big is the India CDMO Market in 2024?
Who are the Key Players in the India CDMO Market?
What is the Projected Growth Rate of the Market through 2031?
What is the Market Forecast for India CDMO by 2032?
Which Region is Estimated to Dominate the India CDMO Industry through the Forecast Period?
Company Insights: Key Players in the India CDMO Market
• Piramal Pharma Solutions
• Syngene International
• Dr. Reddy’s Laboratories
• Divi’s Laboratories
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
• Glenmark Pharmaceuticals
• Capsule Pharma
• Laurus Labs
• Strides Pharma Science
Recent Industry Developments
• Lupin Limited launched a new CDMO business in June 2024 under the brand “Lupin Manufacturing Solutions (LMS)”, with Abdelaziz Toumi appointed as CEO, marking its strategic expansion into high-value outsourcing services.
• Aurigene Pharmaceutical Services announced a $40 million investment in May 2023 for a state-of-the-art biologics facility at Genome Valley, Hyderabad, aimed at manufacturing therapeutic proteins, antibodies, and viral vectors.
Conclusion
The India CDMO market is on a strong upward trajectory, supported by global trends in pharmaceutical outsourcing, India’s low-cost manufacturing advantages, and a growing reputation for regulatory compliance and quality. As the demand for generics, biosimilars, and biologics accelerates worldwide, India is poised to consolidate its leadership position in the global CDMO ecosystem.
However, to maintain this momentum, India must address existing infrastructure and technology gaps, particularly in the biologics and advanced therapeutics space. With ongoing investments, strategic partnerships, and government support, the India CDMO market presents an unparalleled opportunity for stakeholders across the pharmaceutical value chain—from manufacturers to investors and global pharma companies looking for reliable outsourcing partners.
Read Related Reports:
